Anika Therapeutics, Inc.
Health
Performance
6.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Anika Therapeutics, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

22.09.2026
Almost falling apart. Core metrics remain shaky and unstable.
12.09.2026
Losing steam. Not trending your way right now.
04.09.2026
Trouble brewing. Volatility and pressure rising.
20.08.2025
Pulse detected. Still fragile, but stabilizing.
ANIK
Anika Therapeutics, Inc.
20.70
-0.53%
6.3
Sell
Buy
Anika Therapeutics, Inc.

Anika Therapeutics, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Anika Therapeutics, Inc. do? Business model and key facts

Get the full picture of Anika Therapeutics, Inc.: what it builds, where it operates, and how it makes money.

Anika Therapeutics, Inc. Profile

Sector: Healthcare

Industry: Medical - Specialties

Employees (FY): 235

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

shop
Company facts
Stephen D. Griffin
CEO
235
Employees worldwide
shop
Performance
121.63%
Last 12 months
-46.58%
Last 5 years
shop
Growth
$112.82M
Revenue year
$-10,880,000
Net income
shop
Valuation
$278.50M
Market Cap
-12.64
Price/Earnings Ratio

Stocks related to Anika Therapeutics, Inc.

Selected based on industry alignment and relative market positioning.

LAB
Standard BioTools Inc.
0.74
-3.62%
9.4
Sell
Buy
Standard BioTools Inc.
MLAB
Mesa Laboratories, Inc.
131.87
+4.21%
5.7
Sell
Buy
Mesa Laboratories, Inc.
STE
STERIS plc
206.97
+0.94%
3.6
Sell
Buy
STERIS plc

Events and news impacting Anika Therapeutics, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Anika Therapeutics, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.